---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-013953"
form_type: "8-K"
ticker: "VVOS"
cik: "0001716166"
company_name: "Vivos Therapeutics, Inc."
filed_at: "2025-09-18T23:59:59+00:00"
generated_at: "2026-05-17T06:15:49.251095+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Vivos DNA appliance shows 77% of pediatric OSA patients achieve ≥50% severity reduction in peer-reviewed trial

## Summary
- 77% of participants had ≥50% reduction in OSA severity; 93% with severe OSA reached that threshold.
- 17% of children achieved complete resolution of OSA; airway volume increased 67.8% on average.
- Pediatric Sleep Questionnaire scores improved 31% – statistically significant.
- Data published in European Journal of Pediatrics; first multicenter trial for DNA appliance in pediatric OSA.
- Study provides evidence for non-surgical alternative to adenotonsillectomy, which is only 20–40% effective.

## SEC filing metadata
- accession: 0001493152-25-013953
- form_type: 8-K
- ticker: VVOS
- cik: 0001716166
- company_name: Vivos Therapeutics, Inc.
- filed_at: 2025-09-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1716166/000149315225013953/0001493152-25-013953-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1716166/000149315225013953/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-013953
- JSON: https://secwatch.observer/filing/0001493152-25-013953.json
- Plain text: https://secwatch.observer/filing/0001493152-25-013953.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.